Adipocyte fatty acid binding protein in atherosclerotic plaques is associated with local vulnerability and is predictive for the occurrence of adverse cardiovascular events

European Heart Journal

Volumn 32, Issue 14, 2011, Pages 1758-1768

  Peeters, Wouter ^a,b   De Kleijn, Dominique P V ^a,b   Vink, Aryan ^a   Van De Weg, Sander ^a   Schoneveld, Arjan H ^a   Sze, Siu Kwan ^c   Van Der Spek, Peter J ^d   De Vries, Jean Paul P M ^e   Moll, Frans L ^a   Pasterkamp, Gerard ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c Nanyang Technological University   (Singapore)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Atherosclerosis; Biomarker; Cardiovascular Outcome; Carotid; FABP4

Indexed keywords

COLLAGEN; FATTY ACID BINDING PROTEIN 4;

ADIPOCYTE; ADULT; ADVERSE CARDIOVASCULAR EVENT; AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLEEDING; CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ENDARTERECTOMY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HUMAN TISSUE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; SMOOTH MUSCLE FIBER; STROKE;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CAROTID ARTERY DISEASES; DEATH, SUDDEN, CARDIAC; DISEASE PROGRESSION; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLAQUE, ATHEROSCLEROTIC; PROGNOSIS; STROKE;

EID: 79960490052     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq387     Document Type: Article

References (33)

1. Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, Hotamisligil GS. Adipocyte fatty acid binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler Thromb Vasc Biol 2002;22: 1686-1691.
2. Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, Hotamisligil GS. Combined adipocyte macrophage fatty acid binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation 2004;110:1492-1498. (Pubitemid 39238029)
3. Layne MD, Patel A, Chen YH, Rebel VI, Carvajal IM, Pellacani A, Ith B, Zhao D, Schreiber BM, Yet SF, Lee ME, Storch J, Perrella MA. Role of macrophage-expressed adipocyte fatty acid binding protein in the development of accelerated atherosclerosis in hypercholesterolemic mice. FASEB J 2001;15:2733-2735.
4. Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, Parker RA, Suttles J, Fazio S, Hotamisligil GS, Linton MF. Lack of macrophage fatty-acid binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 2001;7:699-705. (Pubitemid 32588026)
5. Makowski L, Hotamisligil GS. The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis. Curr Opin Lipidol 2005;16:543-548. (Pubitemid 41376904)
6. Makowski L, Brittingham KC, Reynolds JM, Suttles J, Hotamisligil GS. The fatty acid binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferatoractivated receptor gamma and IkappaB kinase activities. J Biol Chem 2005;280: 12888-12895.
7. Perrella MA, Pellacani A, Layne MD, Patel A, Zhao D, Schreiber BM, Storch J, Feinberg MW, Hsieh CM, Haber E, Lee ME. Absence of adipocyte fatty acid binding protein prevents the development of accelerated atherosclerosis in hypercholesterolemic mice. FASEB J 2001;15:1774-1776.
8. Furuhashi M, Tuncman G, Gorgun CZ, Makowski L, Atsumi G, Vaillancourt E, Kono K, Babaev VR, Fazio S, Linton MF, Sulsky R, Robl JA, Parker RA, Hotamisligil GS. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid binding protein aP2. Nature 2007;447:959-965. (Pubitemid 46975747)
9. Furuhashi M, Hotamisligil GS. Fatty acid binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 2008;7:489-503. (Pubitemid 351767117)
10. Fu Y, Luo N, Lopes-Virella MF, Garvey WT. The adipocyte lipid binding protein (ALBP/aP2) gene facilitates foam cell formation in human THP-1 macrophages. Atherosclerosis 2002;165:259-269. (Pubitemid 35333352)
11. Dalager S, Falk E, Kristensen IB, Paaske WP. Plaque in superficial femoral arteries indicates generalized atherosclerosis and vulnerability to coronary death: an autopsy study. J Vasc Surg 2008;47:296-302. (Pubitemid 351181258)
12. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695.
13. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999;340:14-22. (Pubitemid 29024679)
14. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340: 115-126.
15. Hellings WE, Peeters W, Moll FL, Pasterkamp G. From vulnerable plaque to vulnerable patient: the search for biomarkers of plaque destabilization. Trends Cardiovasc Med 2007;17:162-171. (Pubitemid 46898844)
16. Verhoeven BA, Velema E, Schoneveld AH, de Vries JP, de BP, Seldenrijk CA, de Kleijn DP, Busser E, van der GY, Moll F, Pasterkamp G. Athero-express: differential atherosclerotic plaque expression of mRNA and protein in relation to cardiovascular events and patient characteristics. Rationale and design. Eur J Epidemiol 2004;19:1127-1133. (Pubitemid 40228502)
17. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991;325:445-453.
18. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995;273: 1421-1428.
19. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998; 351:1379-1387.
20. Halliday A, Mansfield A, Marro J, Peto C, Peto R, Potter J, Thomas D. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 2004;363:1491-1502.
21. Rothwell PM, Eliasziw M, Gutnikov SA, Fox AJ, Taylor DW, Mayberg MR, Warlow CP, Barnett HJ. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 2003;361: 107-116. (Pubitemid 36092014)
22. Verhoeven B, Hellings WE, Moll FL, de Vries JP, de Kleijn DP, de BP, Busser E, Schoneveld AH, Pasterkamp G. Carotid atherosclerotic plaques in patients with transient ischemic attacks and stroke have unstable characteristics compared with plaques in asymptomatic and amaurosis fugax patients. J Vasc Surg 2005; 42:1075-1081. (Pubitemid 41817158)
23. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993;69:377-381. (Pubitemid 23171108)
24. Hellings WE, Pasterkamp G, Vollebregt A, Seldenrijk CA, de Vries JP, Velema E, de Kleijn DP, Moll FL. Intraobserver and interobserver variability and spatial differences in histologic examination of carotid endarterectomy specimens. J Vasc Surg 2007;46:1147-1154. (Pubitemid 350267075)
25. Newby AC. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol 2008; 28:2108-2114.
26. Pasterkamp G, Schoneveld AH, van der Wal AC, Haudenschild CC, Clarijs RJ, Becker AE, Hillen B, Borst C. Relation of arterial geometry to luminal narrowing and histologic markers for plaque vulnerability: the remodeling paradox. J Am Coll Cardiol 1998;32:655-662. (Pubitemid 28435249)
27. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;89:36-44. (Pubitemid 24026469)
28. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000;20:1262-1275. (Pubitemid 30262927)
29. Fu Y, Luo N, Lopes-Virella MF. Oxidized LDL induces the expression of ALBP/aP2 mRNA and protein in human THP-1 macrophages. J Lipid Res 2000;41: 2017-2023. (Pubitemid 32038997)
30. Hellings WE, Peeters W, Moll FL, Piers SR, van Setten J, Van der Spek PJ, de Vries JP, Seldenrijk KA, De Bruin PC, Vink A, Velema E, de Kleijn DP, Pasterkamp G. Composition of carotid atherosclerotic plaque is associated with cardiovascular outcome: a prognostic study. Circulation 2010;121: 1941-1950.
31. Koh JH, Shin YG, Nam SM, Lee MY, Chung CH, Shin JY. Serum adipocyte fatty acid binding protein levels are associated with nonalcoholic fatty liver disease in type 2 diabetic patients. Diabetes Care 2009;32:147-152.
32. Yeung DC, Xu A, Cheung CW, Wat NM, Yau MH, Fong CH, Chau MT, Lam KS. Serum adipocyte fatty acid binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27: 1796-1802. (Pubitemid 47207176)
33. Tuncman G, Erbay E, Hom X, De Vivo I, Campos H, Rimm EB, Hotamisligil GS. A genetic variant at the fatty acid binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc Natl Acad Sci USA 2006;103:6970-6975.